GNMSF (Genmab AS) Net Margin % : 59.70% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Genmab AS Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Genmab AS's Net Income for the three months ended in Dec. 2024 was $540 Mil. Genmab AS's Revenue for the three months ended in Dec. 2024 was $904 Mil. Therefore, Genmab AS's net margin for the quarter that ended in Dec. 2024 was 59.70%.

The historical rank and industry rank for Genmab AS's Net Margin % or its related term are showing as below:

GNMSF' s Net Margin % Range Over the Past 10 Years
Min: 26.42 Med: 43.53 Max: 67.39
Current: 36.44

GNMSF's Net Margin % is ranked better than
94.61% of 1002 companies
in the Biotechnology industry
Industry Median: -135.865 vs GNMSF: 36.44

Genmab AS Net Margin % Historical Data

The historical data trend for Genmab AS's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Net Margin % Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Margin %

Get a 7-Day Free Trial

47.06

35.13

37.59

26.42

36.44

Genmab AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Net Margin %	Get a 7-Day Free Trial															14.77	31.98	26.06	22.85	59.70

Competitive Comparison of Genmab AS's Net Margin %

For the Biotechnology subindustry, Genmab AS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Net Margin % distribution charts can be found below:

* The bar in red indicates where Genmab AS's Net Margin % falls into.

Genmab AS Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Genmab AS's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	1101.361	/	3022.423
	=	36.44 %

Genmab AS's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin	=	Net Income (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	539.869	/	904.368
	=	59.70 %

Genmab AS (OTCPK:GNMSF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Genmab AS Net Margin % Related Terms

Thank you for viewing the detailed overview of Genmab AS's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OTCPK:GNMSF) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.